1-2 of 2
Sabine Blum
Close
Sort by
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial

Clinical Trials & Observations
Rudolf Benz, Kornelius Arn, Martin Andres, Thomas Pabst, Michael Baumann, Urban Novak, Felicitas Hitz, Urs Hess, Reinhard Zenhaeusern, Yves Chalandon, Ulrich Mey, Sabine Blum, Daniel Rauch, Alix O'Meara Stern, Nathan Cantoni, Mario Bargetzi, Elena Bianchi-Papina, Davide Rossi, Jakob Passweg, Andreas Lohri, Simona Berardi, Qiyu Li, Anita Feller, Georg Stussi
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3699–3707.
https://doi.org/10.1182/bloodadvances.2020002160
Published: 2020
Includes: Supplemental data